NCT06027554View on ClinicalTrials.gov

The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 7, 2024

Primary Completion Date

September 1, 2025

Study Completion Date

July 1, 2027

Conditions
FrailtyMild Cognitive ImpairmentAging
Interventions
DRUG

Mitoquinone Mesylate

MitoQ given 20 mg per day for 12 weeks.

DIETARY_SUPPLEMENT

Placebo capsule

Placebo capsule taken every day for 12 weeks.

Trial Locations (1)

06030

RECRUITING

UConn Health, Farmington

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

University of Connecticut

OTHER

lead

UConn Health

OTHER